Eli Lilly and Company (NYSE:LLY) Shares Purchased by Market Street Wealth Management Advisors LLC

Market Street Wealth Management Advisors LLC increased its position in shares of Eli Lilly and Company (NYSE:LLY) by 10.7% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 15,287 shares of the company’s stock after buying an additional 1,475 shares during the quarter. Eli Lilly and Company comprises 2.4% of Market Street Wealth Management Advisors LLC’s investment portfolio, making the stock its 15th biggest holding. Market Street Wealth Management Advisors LLC’s holdings in Eli Lilly and Company were worth $13,840,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Tidemark LLC acquired a new position in shares of Eli Lilly and Company in the fourth quarter valued at approximately $29,000. Core Wealth Advisors Inc. increased its holdings in shares of Eli Lilly and Company by 188.2% in the fourth quarter. Core Wealth Advisors Inc. now owns 49 shares of the company’s stock valued at $29,000 after purchasing an additional 32 shares during the period. Lynx Investment Advisory acquired a new position in shares of Eli Lilly and Company in the second quarter valued at approximately $32,000. Frank Rimerman Advisors LLC acquired a new position in shares of Eli Lilly and Company in the fourth quarter valued at approximately $37,000. Finally, St. Johns Investment Management Company LLC increased its holdings in shares of Eli Lilly and Company by 123.3% in the fourth quarter. St. Johns Investment Management Company LLC now owns 67 shares of the company’s stock valued at $39,000 after purchasing an additional 37 shares during the period. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Insider Activity

In related news, major shareholder Lilly Endowment Inc sold 210,000 shares of the stock in a transaction dated Wednesday, July 10th. The stock was sold at an average price of $939.82, for a total value of $197,362,200.00. Following the completion of the transaction, the insider now owns 96,943,810 shares of the company’s stock, valued at $91,109,731,514.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other Eli Lilly and Company news, EVP Johna Norton sold 7,056 shares of the stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $819.38, for a total transaction of $5,781,545.28. Following the transaction, the executive vice president now owns 25,428 shares of the company’s stock, valued at approximately $20,835,194.64. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, major shareholder Lilly Endowment Inc sold 210,000 shares of the stock in a transaction that occurred on Wednesday, July 10th. The stock was sold at an average price of $939.82, for a total value of $197,362,200.00. Following the transaction, the insider now directly owns 96,943,810 shares in the company, valued at approximately $91,109,731,514.20. The disclosure for this sale can be found here. Over the last quarter, insiders sold 1,097,883 shares of company stock worth $972,022,568. 0.13% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of analysts recently weighed in on LLY shares. Cantor Fitzgerald restated an “overweight” rating and issued a $885.00 price target on shares of Eli Lilly and Company in a research note on Monday, August 19th. Berenberg Bank upped their price objective on Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the company a “buy” rating in a research report on Wednesday, August 14th. Bank of America upped their price objective on Eli Lilly and Company from $1,000.00 to $1,125.00 and gave the company a “buy” rating in a research report on Friday, August 9th. Deutsche Bank Aktiengesellschaft upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating and upped their price objective for the company from $725.00 to $1,025.00 in a research report on Monday, August 12th. Finally, JPMorgan Chase & Co. upped their target price on Eli Lilly and Company from $900.00 to $1,000.00 and gave the company an “overweight” rating in a research note on Thursday, July 11th. Two research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $961.76.

Eli Lilly and Company Trading Up 2.1 %

NYSE:LLY traded up $19.82 on Friday, hitting $960.02. 2,456,992 shares of the stock were exchanged, compared to its average volume of 3,070,253. The stock has a market cap of $912.41 billion, a PE ratio of 141.39, a PEG ratio of 1.81 and a beta of 0.41. The company has a current ratio of 1.35, a quick ratio of 1.03 and a debt-to-equity ratio of 1.90. The stock has a fifty day moving average of $891.13 and a 200-day moving average of $819.99. Eli Lilly and Company has a fifty-two week low of $516.57 and a fifty-two week high of $972.53.

Eli Lilly and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 10th. Stockholders of record on Thursday, August 15th will be paid a $1.30 dividend. The ex-dividend date is Thursday, August 15th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 0.54%. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 76.58%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.